QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
NASDAQ:CMRX

Chimerix (CMRX) Stock Forecast, Price & News

$1.39
+0.01 (+0.72%)
(As of 06/1/2023 ET)
Compare
Today's Range
$1.36
$1.44
50-Day Range
$1.10
$1.44
52-Week Range
$1.09
$2.90
Volume
641,220 shs
Average Volume
846,793 shs
Market Capitalization
$123.13 million
P/E Ratio
0.70
Dividend Yield
N/A
Price Target
$8.33

Chimerix MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
499.5% Upside
$8.33 Price Target
Short Interest
Healthy
4.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.49
Upright™ Environmental Score
News Sentiment
0.51mentions of Chimerix in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$113,093 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.92) to ($0.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.96 out of 5 stars

Medical Sector

51st out of 1,980 stocks

Pharmaceutical Preparations Industry

17th out of 978 stocks


CMRX stock logo

About Chimerix (NASDAQ:CMRX) Stock

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

CMRX Stock News Headlines

The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
JonesTrading Sticks to Its Buy Rating for Chimerix (CMRX)
Brokerages Set Chimerix, Inc. (NASDAQ:CMRX) PT at $8.50
5 Best Stocks to Buy for the Next 10 Years
Chimerix's Earnings Outlook
JonesTrading Keeps Their Buy Rating on Chimerix (CMRX)
See More Headlines

CMRX Price History

CMRX Company Calendar

Last Earnings
3/02/2023
Today
6/01/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CMRX
Employees
87
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$8.33
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+499.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$172.17 million
Pretax Margin
515.07%

Debt

Sales & Book Value

Annual Sales
$33.82 million
Cash Flow
$1.96 per share
Book Value
$2.71 per share

Miscellaneous

Free Float
81,320,000
Market Cap
$123.13 million
Optionable
Optionable
Beta
1.15

Social Links


Key Executives

  • Michael A. Sherman
    President, Chief Executive Officer & Director
  • Michael T. Andriole
    Chief Financial & Business Officer
  • Roy W. Ware
    Chief Technology & Manufacturing Officer
  • Caryn Barnett
    Vice President-Clinical Operations
  • Allen Melemed
    Chief Medical Officer













CMRX Stock - Frequently Asked Questions

Should I buy or sell Chimerix stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CMRX shares.
View CMRX analyst ratings
or view top-rated stocks.

What is Chimerix's stock price forecast for 2023?

3 brokerages have issued twelve-month price objectives for Chimerix's shares. Their CMRX share price forecasts range from $7.00 to $11.00. On average, they expect the company's stock price to reach $8.33 in the next twelve months. This suggests a possible upside of 499.5% from the stock's current price.
View analysts price targets for CMRX
or view top-rated stocks among Wall Street analysts.

How have CMRX shares performed in 2023?

Chimerix's stock was trading at $1.86 at the start of the year. Since then, CMRX stock has decreased by 25.3% and is now trading at $1.39.
View the best growth stocks for 2023 here
.

Are investors shorting Chimerix?

Chimerix saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 3,720,000 shares, a decline of 9.3% from the April 30th total of 4,100,000 shares. Based on an average trading volume of 945,700 shares, the days-to-cover ratio is currently 3.9 days. Approximately 5.0% of the company's stock are short sold.
View Chimerix's Short Interest
.

When is Chimerix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CMRX earnings forecast
.

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) released its earnings results on Thursday, March, 2nd. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.24). The biopharmaceutical company earned $0.81 million during the quarter, compared to the consensus estimate of $2.60 million. Chimerix had a net margin of 514.97% and a trailing twelve-month return on equity of 87.89%. During the same quarter last year, the business posted ($0.45) EPS.

What ETFs hold Chimerix's stock?

ETFs with the largest weight of Chimerix (NASDAQ:CMRX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS) and ETFMG Treatments Testing and Advancements ETF (GERM) and

What other stocks do shareholders of Chimerix own?
What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Who are Chimerix's major shareholders?

Chimerix's stock is owned by many different institutional and retail investors. Top institutional investors include Rubric Capital Management LP (8.28%), BlackRock Inc. (5.52%), Armistice Capital LLC (3.70%), State Street Corp (2.59%), Acadian Asset Management LLC (2.25%) and AQR Capital Management LLC (2.15%). Insiders that own company stock include David Jakeman, Fred A Middleton, Martha J Demski, Michael T Andriole and Robert J Meyer.
View institutional ownership trends
.

How do I buy shares of Chimerix?

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $1.39.

How much money does Chimerix make?

Chimerix (NASDAQ:CMRX) has a market capitalization of $123.13 million and generates $33.82 million in revenue each year. The biopharmaceutical company earns $172.17 million in net income (profit) each year or $2.00 on an earnings per share basis.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The official website for the company is www.chimerix.com. The biopharmaceutical company can be reached via phone at (919) 806-1074, via email at ir@chimerix.com, or via fax at 919-806-1146.

This page (NASDAQ:CMRX) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -